0001217234-25-000063
SEC filingRevenue grew 21% YoY to $100.1M, driven by testing services volume growth, with net income of $1.7M vs prior year loss.
CareDx reported a strong third quarter in 2025, with total revenue of $100.1M, a 21% increase year-over-year from $82.9M in Q3 2024. The growth was driven by all three revenue segments. Testing services revenue rose 19% to $72.2M, supported by a 13% increase in testing volume and improved collection rates under ASC 606. Product revenue grew 22% to $12.5M, primarily due to higher sales of NGS-based kitted solutions. Patient and digital solutions revenue surged 30% to $15.4M, reflecting expansion of the Ottr software platform and increased pharmacy sales.
The company swung to net income of $1.7M compared to a net loss of $10.6M in the prior year, a $12.3M improvement. Operating loss narrowed to $0.2M from $13.7M, as revenue growth outpaced operating expense increases. Gross profit (not explicitly stated but calculated) improved, with total cost of revenue increasing only 12% versus revenue growth of 21%, indicating margin expansion.
The testing services segment remains the core driver, contributing 72% of total revenue. The 19% revenue growth outpaced volume growth of 13%, aided by revenue recognition adjustments. Product revenue accelerated to 22% growth, benefiting from new customer conversions and increased adoption of NGS-based products. Patient and digital solutions posted the fastest growth at 30%, with digital solutions led by Ottr software gaining traction and pharmacy sales benefiting from the TTP acquisition.
Cost efficiency measures were evident across segments. Cost of testing services increased only 9% despite volume growth, aided by lower laboratory expenses. Cost of product declined 9% due to improved manufacturing efficiencies and favorable pricing. Cost of patient and digital solutions increased 30%, in line with revenue growth, reflecting the variable cost nature of pharmacy sales.
Management highlighted several strategic priorities: continued investment in R&D for new transplant diagnostic solutions, expansion of biopharma partnerships (e.g., AlloCell), and market penetration of Ottr and XynQAPI software. The company ended the quarter with $194.2M in cash and no debt, providing ample liquidity. A $50M share repurchase program remains active with $24.4M remaining. No explicit numerical guidance was provided, but management expressed confidence in sustaining momentum through volume growth, reimbursement improvements, and cost discipline. Key risks include payer coverage decisions and competitive dynamics in the transplant diagnostics market.
As of September 30, 2025, CareDx held $91.4M in cash and cash equivalents and $102.8M in marketable securities, totaling $194.2M. Total assets were $432.3M, with shareholder equity of $311.1M. The company has no debt (excluding lease liabilities). Inventory increased to $28.3M from $19.5M at year-end. Deferred revenue was $5.8M.
Operating lease commitments total $31.7M, with $8.0M due within one year. Royalty commitments under license agreements with Illumina and a university require mid-single to low-double digit royalties on product sales. A collaboration agreement for iBox includes revenue sharing. The company accrued $20.25M for a securities class action settlement, partially offset by $14.9M expected insurance recovery. No supply purchase commitments were disclosed.
During the nine months ended September 30, 2025, CareDx repurchased 5.0M shares for $75.6M under two board-authorized programs ($50M each). The February 2025 program was fully utilized, and $24.4M remained under the May 2025 program as of September 30. Capital expenditures totaled $3.9M (1.4% of revenue). No dividends were paid, and there was no material debt activity.
The company operates as a single reportable segment. Revenue is derived from three sources: testing services ($196.1M), product ($35.1M), and patient and digital solutions ($40.2M) for the nine months ended September 30, 2025. Geographically, U.S. revenue was $256.6M (94.5% of total) and Rest of World was $14.9M. Long-lived assets were concentrated in the U.S. ($30.6M). The CODM uses net income as the primary profit measure.
CFO of $20.7M significantly exceeded net loss of ($17.2M), reflecting large non-cash charges (stock compensation $26.8M, D&A $11.1M) and favorable working capital, notably a $17.2M decrease in AR. Capex of $3.9M was 19% of CFO, indicating low capital intensity. Implied FCF of $16.7M covered 22% of share repurchases ($75.6M), which were financed largely by investing cash inflows from marketable securities ($41.7M net maturities).